Mocetinostat

Phase 1Small molecule

MMirati Therapeutics Inc.

Mocetinostat is one of 71 small molecule programs targeting Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

RhabdomyosarcomaActive, not recruiting

Lung CancerPhase 1

Active, not recruiting

RhabdomyosarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

25 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Tecentriq

Roche

Phase 3

6 5

Alecensa

Roche

Phase 3

3 6

Zepzelca

Jazz Pharmaceuticals

Phase 3

3 7

DATROWAY

Daiichi Sankyo

Phase 3

2 8

Tarlatamab-Dznl

Amgen

Phase 3

2 9

Ilaris

Novartis

Phase 3

2 10

Hycamtin

MMeitheal

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Lung Cancer

NCT03220477

Q4 2027

Phase 1Active, not recruiting

Rhabdomyosarcoma

NCT04299113

Clinical

Trials by Indication[1]

Leiomyosarcoma1 trial

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02303262·20 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02282358·7 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Terminated·MMirati Therapeutics Inc.·Phase 2·NCT02954991·161 enrolled

Urothelial Carcinoma1 trial

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Completed·MMirati Therapeutics Inc.·Phase 2·NCT02236195·17 enrolled

Squamous Cell Carcinoma1 trial

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Withdrawn·UUniversity Health Network, Toronto·Phase 1·NCT02993991

4 more indications

MDS1 trial

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Completed·MMirati Therapeutics Inc.·Phase 1/2·NCT02018926·18 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Terminated·MMirati Therapeutics Inc.·Phase 1/2·NCT02805660·83 enrolled

Lung Cancer1 trial

Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03220477·28 enrolled

Rhabdomyosarcoma1 trial

A Phase I Dose Escalation/Expansion Clinical Trial of Mocetinostat in Combination With Vinorelbine in Children, Adolescents and Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma (RMS)

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04299113·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Mocetinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mocetinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mocetinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirati Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMirati Therapeutics Inc.

Mocetinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Leiomyosarcoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Non-Small Cell Lung Cancer1 trial

Urothelial Carcinoma1 trial

Squamous Cell Carcinoma1 trial

MDS1 trial

Patients With Advanced Solid Tumors1 trial

Lung Cancer1 trial

Rhabdomyosarcoma1 trial

References

Drug Info

Quick Facts

Related News